QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
NASDAQ:CPIX

Cumberland Pharmaceuticals Stock Forecast, Price & News

$4.10
-0.93 (-18.49%)
(As of 12/1/2021 04:00 PM ET)
Add
Compare
Today's Range
$3.67
$4.40
50-Day Range
$2.20
$5.03
52-Week Range
$2.20
$5.48
Volume
12.64 million shs
Average Volume
1.07 million shs
Market Capitalization
$60.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.23
30 days | 90 days | 365 days | Advanced Chart
Receive CPIX News and Ratings via Email

Sign-up to receive the latest news and ratings for Cumberland Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Cumberland Pharmaceuticals logo

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:CPIX
CUSIP
23077010
Employees
90
Year Founded
1999

Sales & Book Value

Annual Sales
$37.44 million
Cash Flow
$0.46 per share
Book Value
$3.12 per share

Profitability

Net Income
$-3.34 million
Pretax Margin
-7.81%

Debt

Price-To-Earnings

Miscellaneous

Free Float
8,710,000
Market Cap
$60.72 million
Optionable
Optionable

Company Calendar

Last Earnings
8/10/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/08/2022

Social Links


MarketRank

Overall MarketRank

1.47 out of 5 stars

Medical Sector

1083rd out of 1,392 stocks

Pharmaceutical Preparations Industry

512th out of 669 stocks

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Cumberland Pharmaceuticals (NASDAQ:CPIX) Frequently Asked Questions

Is Cumberland Pharmaceuticals a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cumberland Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Cumberland Pharmaceuticals stock.
View analyst ratings for Cumberland Pharmaceuticals
or view top-rated stocks.

How has Cumberland Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Cumberland Pharmaceuticals' stock was trading at $4.14 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CPIX stock has decreased by 1.0% and is now trading at $4.10.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 4,000 shares, a decline of 95.4% from the October 31st total of 87,000 shares. Based on an average trading volume of 37,800 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.1% of the company's stock are short sold.
View Cumberland Pharmaceuticals' Short Interest
.

When is Cumberland Pharmaceuticals' next earnings date?

Cumberland Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Cumberland Pharmaceuticals
.

How were Cumberland Pharmaceuticals' earnings last quarter?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released its quarterly earnings data on Tuesday, August, 10th. The specialty pharmaceutical company reported $0.08 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.09) by $0.17. The specialty pharmaceutical company earned $9.06 million during the quarter, compared to analysts' expectations of $8.57 million. Cumberland Pharmaceuticals had a positive trailing twelve-month return on equity of 0.37% and a negative net margin of 1.43%.
View Cumberland Pharmaceuticals' earnings history
.

Who are Cumberland Pharmaceuticals' key executives?

Cumberland Pharmaceuticals' management team includes the following people:
  • A. J. Kazimi, Chairman & Chief Executive Officer
  • Leo B. Pavliv, Chief Development Officer & EVP-Operations
  • John Hamm, Chief Financial & Accounting Officer
  • Martin E. Cearnal, Director, Chief Compliance Officer & Executive VP (LinkedIn Profile)
  • James L. Herman, Chief Compliance Officer & Senior Vice President

What is A. J. Kazimi's approval rating as Cumberland Pharmaceuticals' CEO?

9 employees have rated Cumberland Pharmaceuticals CEO A. J. Kazimi on Glassdoor.com. A. J. Kazimi has an approval rating of 9% among Cumberland Pharmaceuticals' employees. This puts A. J. Kazimi in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cumberland Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cumberland Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), CymaBay Therapeutics (CBAY), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Akero Therapeutics (AKRO), Cerecor (CERC), CorMedix (CRMD) and Xeris Pharmaceuticals (XERS).

What is Cumberland Pharmaceuticals' stock symbol?

Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPIX."

Who are Cumberland Pharmaceuticals' major shareholders?

Cumberland Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (4.68%), Renaissance Technologies LLC (4.47%), BlackRock Inc. (2.24%), Berkshire Asset Management LLC PA (1.18%), Citadel Advisors LLC (0.08%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Cumberland Pharmaceuticals stock include A J Kazimi, A J Kazimi, Gordon R Bernard, Joseph C Galante, Kenneth Krogulski, Martin E Cearnal, Martin E Cearnal and William Sumas.
View institutional ownership trends for Cumberland Pharmaceuticals
.

Which institutional investors are selling Cumberland Pharmaceuticals stock?

CPIX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, and Renaissance Technologies LLC.
View insider buying and selling activity for Cumberland Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Cumberland Pharmaceuticals stock?

CPIX stock was acquired by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, and Berkshire Asset Management LLC PA. Company insiders that have bought Cumberland Pharmaceuticals stock in the last two years include A J Kazimi, Joseph C Galante, Kenneth Krogulski, and Martin E Cearnal.
View insider buying and selling activity for Cumberland Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Cumberland Pharmaceuticals?

Shares of CPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cumberland Pharmaceuticals' stock price today?

One share of CPIX stock can currently be purchased for approximately $4.10.

How much money does Cumberland Pharmaceuticals make?

Cumberland Pharmaceuticals has a market capitalization of $60.72 million and generates $37.44 million in revenue each year. The specialty pharmaceutical company earns $-3.34 million in net income (profit) each year or ($0.04) on an earnings per share basis.

How many employees does Cumberland Pharmaceuticals have?

Cumberland Pharmaceuticals employs 90 workers across the globe.

When was Cumberland Pharmaceuticals founded?

Cumberland Pharmaceuticals was founded in 1999.

What is Cumberland Pharmaceuticals' official website?

The official website for Cumberland Pharmaceuticals is www.cumberlandpharma.com.

Where are Cumberland Pharmaceuticals' headquarters?

Cumberland Pharmaceuticals is headquartered at 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203.

How can I contact Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals' mailing address is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. The specialty pharmaceutical company can be reached via phone at (615) 255-0068, via email at [email protected], or via fax at 615-255-0094.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.